Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).
Clarity Pharmaceuticals has announced that director Colin David Biggin has ceased to be a director of the company as of 8 April 2026. A final director’s interest notice filed with the ASX details that Biggin retains holdings in the company, including millions of fully paid ordinary shares and multiple tranches of options with different exercise prices and expiry dates, ensuring his ongoing financial alignment with Clarity despite his board departure.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.41 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is an Australian-listed company in the pharmaceuticals sector. The company focuses on developing and commercialising medical products, with its equity securities including fully paid ordinary shares and a range of options with varying exercise prices and maturities, reflecting an incentive-heavy capital structure typical for growth-stage life sciences firms.
Average Trading Volume: 2,135,012
Technical Sentiment Signal: Sell
Current Market Cap: A$1.14B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.